SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 54.92-3.6%12:24 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: JamesK who wrote (51965)7/24/2022 2:31:42 PM
From: A.J. Mullen  Read Replies (1) of 52153
 
Thanks again for bringing the prices of options in ALNY to my attention. I sold half my holdings and also sold puts for the same number of shares. If the FDA decision goes against the company, I could end up with the original number of shares at a lower net cost. $20 a share seemed a reasonable premium for the risk of a decline greater than 23% given the company isn't a one-trick pony. Otherwise, I've halved my exposure to mediocre and blow-out moves.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News